<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="http://medicalxpress.com/tmpl/default/css/default/feedRSS.xsl"?>
<rss version="2.0" 
	xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Medical Xpress: University of Missouri School of Medicine in the news</title>
<link>http://medicalxpress.com/</link>
<language>en-us</language> 
<description>Medical Xpress provides the latest news from University of Missouri School of Medicine</description>

 <item>
     <title>New research shows weekend binge drinking could leave lasting liver damage</title>
   	 <description>Long after a hangover, a night of bad decisions might take a bigger toll on the body than previously understood. Described in the current issue of Alcoholism: Clinical &amp; Experimental Research, a study at the University of Missouri has revealed a unique connection between binge drinking and the risk for developing alcoholic liver disease and a variety of other health problems.</description>
     <link>http://medicalxpress.com/news/2013-05-weekend-binge-liver.html</link>
	 <category>Health</category>
	 <pubDate>Wed, 01 May 2013 12:02:55 EST</pubDate>
	 <guid isPermaLink="false">news286628565</guid>
	 
</item>
<item>
     <title>Discovery could increase efficacy of promising cystic fibrosis drug</title>
   	 <description>(Medical Xpress)—A little more than a year after the FDA approved Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, University of Missouri researchers believe they have found exactly how this drug works and how to improve its effectiveness in the future. Described in the current issue of the Proceedings of the National Academy of Sciences, MU researchers have redefined a key regulatory process in the defective protein responsible for cystic fibrosis that could change the way scientists approach the lethal genetic disease.</description>
     <link>http://medicalxpress.com/news/2013-03-discovery-efficacy-cystic-fibrosis-drug.html</link>
	 <category>Medical research</category>
	 <pubDate>Thu, 21 Mar 2013 14:21:27 EST</pubDate>
	 <guid isPermaLink="false">news283094460</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/discoverycou.jpg" width="90" height="90" />
</item>
<item>
     <title>Scientists discover 'needle in a haystack' for muscular dystrophy patients</title>
   	 <description>(Medical Xpress)—Muscular dystrophy is caused by the largest human gene, a complex chemical leviathan that has confounded scientists for decades. Research conducted at the University of Missouri and described this month in the Proceedings of the National Academy of Sciences has identified significant sections of the gene that could provide hope to young patients and families.</description>
     <link>http://medicalxpress.com/news/2013-01-scientists-needle-haystack-muscular-dystrophy.html</link>
	 <category>Medical research</category>
	 <pubDate>Tue, 22 Jan 2013 15:11:27 EST</pubDate>
	 <guid isPermaLink="false">news278089867</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/5-scientistsdi.jpg" width="90" height="90" />
</item>
<item>
     <title>Researchers attack HIV's final defenses before drug-resistant mutations emerge</title>
   	 <description>Scientists who study HIV are facing a troubling consequence of their own success. They created drugs that can now give infected patients almost normal life expectancy. However, those same drugs will eventually cause the constantly mutating virus to evolve into a form that eludes current treatments.</description>
     <link>http://medicalxpress.com/news/2013-01-hiv-defenses-drug-resistant-mutations-emerge.html</link>
	 <category>HIV &amp; AIDS</category>
	 <pubDate>Wed, 16 Jan 2013 16:16:46 EST</pubDate>
	 <guid isPermaLink="false">news277575401</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2013/researchersa.jpg" width="90" height="90" />
</item>
<item>
     <title>New stroke treatment could prevent and reduce brain damage</title>
   	 <description>Researchers at the University of Missouri have demonstrated the effectiveness of a potential new therapy for stroke patients in an article published in the journal Molecular Neurodegeneration. Created to target a specific enzyme known to affect important brain functions, the new compound being studied at MU is designed to stop the spread of brain bleeds and protect brain cells from further damage in the crucial hours after a stroke.</description>
     <link>http://medicalxpress.com/news/2012-06-treatment-brain.html</link>
	 <category>Neuroscience</category>
	 <pubDate>Mon, 11 Jun 2012 12:42:58 EST</pubDate>
	 <guid isPermaLink="false">news258637296</guid>
	 <media:thumbnail url="http://s.ph-cdn.com/newman/gfx/news/tmb/2012/newstroketre.jpg" width="90" height="90" />
</item>


</channel>
</rss>
